Publication details
The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | BIOMARKERS IN MEDICINE |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.futuremedicine.com/doi/10.2217/BMM.14.105 |
| Doi | http://dx.doi.org/10.2217/BMM.14.105 |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | alpha-synuclein; biomarker; CSF; diagnosis; ELISA; Parkinson's disease |
| Attached files | |
| Description | The discovery of -synuclein (-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of -syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of -syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of -syn has yielded novel insights into the variety of -syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of -syn as biomarker. We also suggest future approaches to use of CSF -syn in neurodegenerative diseases. |
| Related projects: |